[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit ::
Main Menu
Journal Information::
Articles Archive::
Guide for Authors::
For Reviewers::
Ethical Statements::
Site Facilities::
Contact us::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Copyright Policies




Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

:: Volume 6 - The Summer Supplement of Shefaye Khatam 2 - ::
Shefaye Khatam 2018, 6 - The Summer Supplement of Shefaye Khatam 2 -: 18-18 Back to browse issues page
O18: Vague Nerve Stimulation
Nasser Zangiabadi *
Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran , N.zangiabadi@gmail.com
Abstract:   (2880 Views)
VNS indications
VNS Therapy system is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients whose epileptic disorder is dominated by partial seizures (with or without secondary generalization) or generalized seizures that are refractory to antiepileptic medications.
VNS Therapy is indicated for the adjunctive long-term treatment of chronic or recurrent depression who are experiencing a major depressive episode and have not had an adequate response to four or more antidepressant treatments.
Mechanism of action
VNS definitely exerts an effect via the LC (norepinephrine) and the RN (serotonin)
These mechanisms of action are similar to those of medications through pharmacologic pathways
The LC and RN/DRN have been conclusively identified as:
  • Brain centers affected by VNS Therapy
  • Playing a role in suppressing seizures
  • Areas that must be intact for VNS Therapy to have an effect
VNS Safety Profile
More than 70,000 patients worldwide have been implanted with VNS Therapy
No known interactions with medications
No reported systemic neurotoxic effects, rash, renal impairment, or bone marrow suppression
No increase in sudden, unexpected death in epilepsy (SUDEP)1
Gestational outcomes
Animal study has shown no evidence of impaired fertility or harm to the fetus due to VNS Therapy2,3
Pregnancies have gone to term with VNS4,5
One of my challenging Cases which resulted in Vague Nerve Stimulation (VNS) therapy
53-year-old Right-handed gentleman with History of epilepsy since 1983 (due to being injured during war) in form of CPS and GTCs.
We implanted VNS for the first time in Khatam-Al-Anbia hospital about three months ago for this patient.
The frequency of the patient’s attacks has been decreased to about eighty percent till now.
No significant side effects have been reported except for mild hoarseness.
Keywords: VNS Therapy, Epilepsy, Systemic Neurotoxic Effects
Full-Text [PDF 239 kb]   (602 Downloads)    
Type of Study: Review --- Open Access, CC-BY-NC | Subject: Basic research in Neuroscience

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Zangiabadi N. O18: Vague Nerve Stimulation. Shefaye Khatam 2018; 6 (S2) :18-18
URL: http://shefayekhatam.ir/article-1-1808-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 6 - The Summer Supplement of Shefaye Khatam 2 - Back to browse issues page
مجله علوم اعصاب شفای خاتم The Neuroscience Journal of Shefaye Khatam
Persian site map - English site map - Created in 0.05 seconds with 45 queries by YEKTAWEB 4657